Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13716: Variant p.Gly133Arg

Delta-aminolevulinic acid dehydratase
Gene: ALAD
Feedback?
Variant information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Arginine (R) at position 133 (G133R, p.Gly133Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AHEPP; mixture of about 50% hexamer and 50% octamer; about 10% residual activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 330 The length of the canonical sequence.
Location on the sequence: help PNLLVACDVCLCPYTSHGHC G LLSENGAFRAEESRQRLAEV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 330 Delta-aminolevulinic acid dehydratase
Binding site 122 – 122
Binding site 124 – 124
Binding site 131 – 131
Binding site 132 – 132
Mutagenesis 122 – 122 C -> A. Reduces enzyme activity about 1000000-fold; when associated with A-124 and A-132.
Mutagenesis 124 – 124 C -> A. Reduces enzyme activity about 1000000-fold; when associated with A-122 and A-132.
Mutagenesis 131 – 131 H -> A. No effect on catalytic activity; when associated with A-223.
Mutagenesis 132 – 132 C -> A. Reduces enzyme activity about 1000000-fold; when associated with A-122 and A-124.
Beta strand 131 – 133



Literature citations
Delta-aminolevulinate dehydratase deficient porphyria: identification of the molecular lesions in a severely affected homozygote.
Plewinska M.; Thunell S.; Holmberg L.; Wetmur J.G.; Desnick R.J.;
Am. J. Hum. Genet. 49:167-174(1991)
Cited for: VARIANTS AHEPP ARG-133 AND MET-275; ALAD porphyria is a conformational disease.
Jaffe E.K.; Stith L.;
Am. J. Hum. Genet. 80:329-337(2007)
Cited for: CHARACTERIZATION OF VARIANTS AHEPP ARG-133; MET-153; TRP-240; THR-274 AND MET-275; CHARACTERIZATION OF VARIANTS LEU-12 AND ASN-59;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.